Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 28.97 -0.4 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.37 | 52 Week High | $18.62 | |||
| Open | $29.08 | 52 Week Low | $2.85 | |||
| Day High | $29.73 | P/E | N/A | |||
| Day Low | $28.49 | EPS | $-1.02 | |||
| Volume | 877,932 | |||||
